The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b

ARDS - Acute lung injury

Publications

Powell NR, Shugg T, Ly RC, Albany C, Radovich M, Schneider BP, Skaar TC

Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report.

Frontiers in oncology. 2021;11:809527

Watad A, Bragazzi N, Grysman Luigi, Mahagna H, Amital H

Lungs in White Induced by Docetaxel.

The Israel Medical Association journal : IMAJ. 2017;19(6):393-394

Gibelin A, Parrot A, Maitre B, Brun-Buisson C, Mekontso Dessap A, Fartoukh M, de Prost N

Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition.

Intensive care medicine. 2016;42(2):164-72

Raufi A, Dotson J, Khasawneh M

Acute Respiratory Distress Syndrome after Treatment of Metastatic Prostate Cancer with Taxotere: A Case Report and Literature Review.

Case reports in urology. 2015;2015:198381

Gurram MK, Pulivarthi S, McGary CT

Fatal hypersensitivity pneumonitis associated with docetaxel.

Tumori. 2013;99(3):e100-3

Storaas E, Holmaas G, Gravdal K, Børretzen A, Eikesdal HP

Lethal pneumonitis after docetaxel chemotherapy: case report and review of the literature.

Acta oncologica (Stockholm, Sweden). 2013;52(5):1034-8

Min BD, Kang HW, Kim WT, Kim YJ, Yun SJ, Lee SC, Kim WJ

Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer.

Korean journal of urology. 2012;53(5):371-4

Kuip E, Muller E

Fatal pneumonitis after treatment with docetaxel and trastuzumab.

The Netherlands journal of medicine. 2009;67(6):237-9

Prat A, Martínez P, Serrano C, Montero MA, Andreu J, Cortés J

Acute lung injury associated with docetaxel and bevacizumab.

Clinical oncology (Royal College of Radiologists (Great Britain)). 2007;19(10):803-5

Leimgruber K, Negro R, Baier S, Moser B, Resch G, Sansone S, Adami M, Zanon P, Graiff C, Egarter-Vigl E, Wiedermann CJ

Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer.

Tumori. 2006;92(6):542-4

Amathieu R, Tual L, Fessenmeyer C, Dhonneur G

[Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema].

Annales francaises d'anesthesie et de reanimation. 2007;26(2):180-1

Morris MJ, Santamauro J, Shia J, Schwartz L, Vander Els N, Kelly K, Scher H

Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.

Urology. 2002;60(6):1111

Read WL, Mortimer JE, Picus J

Severe interstitial pneumonitis associated with docetaxel administration.

Cancer. 2002;94(3):847-53

Wang GS, Yang KY, Perng RP

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere).

British journal of cancer. 2001;85(9):1247-50